Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772011 | 0.91 | MAPT (0.44) | CYP11B2CYP11B1HRH3PANK3MAPT | |
| SCHEMBL3773946 | 0.89 | IL4I1 (0.43) | HRH3PANK3MAPTKDM4EALDH1A1 | |
| SCHEMBL3773851 | 0.89 | HRH3 (0.47) | CYP11B2CYP11B1HRH3KDM4EALDH1A1 | |
| SCHEMBL3767633 | 0.87 | HRH3 (0.46) | CYP11B2CYP11B1HRH3MAPTALDH1A1 | |
| SCHEMBL3774609 | 0.86 | HRH3 (0.47) | CYP11B2CYP11B1HRH3MAPTGRIN2B | |
| SCHEMBL3771420 | 0.86 | HRH3 (0.41) | CYP11B2CYP11B1HRH3PANK3GRIN2B | |
| SCHEMBL3770359 | 0.86 | CYP11B1 (0.44) | CYP11B2CYP11B1HRH3PANK3MAPT | |
| SCHEMBL3774809 | 0.86 | MAPT (0.44) | CYP11B2CYP11B1HRH3PANK3MAPT | |
| SCHEMBL3770272 | 0.85 | CYP11B1 (0.44) | CYP11B2CYP11B1HRH3MAPT | |
| SCHEMBL3767828 | 0.85 | HRH3 (0.40) | CYP11B2CYP11B1HRH3PANK3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | CYP11B2 1877/4885CYP11B1 2263/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.